drugset / Trial / NCT02484170

Mannitol Cream for Post Herpetic Neuralgia

NCT02484170

Phase 1/2 Completed 20 enrolled University of British Columbia
RandomizedCrossoverQuadruple-blindTreatment

Summary

30% mannitol cream has shown its ability to reduce the activation of the Capsaicin (TRPV1) (Transient Receptor Potential Vanilloid 1) receptor, a likely cause of the pain of post-herpetic neuralgia (PHN). This randomized placebo-controlled crossover study compares PHN pain one week before, for one week on the randomly assigned mannitol versus placebo cream and, after a three day washout, for one week on the other cream. Following this crossover study, participants receive mannitol cream for three months. Pain levels will be checked to assess whether continued use of this cream significantly reduces the pain levels associated with PHN. If pain persists beyond 3 months, participants will be offered mannitol and menthol cream for one month following which their pain levels will be checked.

Timeline

Start
2015-09-30
Primary completion
2016-04-29
Completion
2017-04-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mannitol Diagnostic / imaging agent 30 % Topical